Research: Shared Services

Translational Laboratory

Current users of the Translational Laboratory are:

For More Information

  1. UMGCC clinicians:
    • Dr. E.A. Sausville (and Dr. P. LoRusso, Wayne State Univ. NCI U01):
      • PD of NCI Phase I: 17-AAG and sorafenib in solid tumors; Hsp90, Hsp70, c-raf-1, CDK4, and pAKT in PBLs (NCI 6972).
      • PD of NCI Phase I: Aminoflavone in breast and renal cell cancer; H2AX and AhR in CTCs.
      • PD of NCI Phase I: A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors.
    • Dr. I. Gojo:
      • Collection and Processing of PD Specimens for Clinical Trial GCC 0507, Industry: A Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemia.
    • Dr. D. Ross:
      • Collection and Processing of PD Specimens for Clinical Trial GCC 0447: A Phase I Study of Vorinostat in Combination with Arabinosyl Cytosine and Etoposide for Patients with Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders (NCI 6829).
    • Dr. M. Edelman:
      • NCI NO1: New Combination Treatments for Lung Cancer (Aurora Kinase Inhibitors and Taxol; Retinoids and HDAC inhibitors: development of optimal treatment schedules and mechanisms of interactions). Dr. Edelman supports a Research Assistant in the laboratory (Anisha DCosta, PhD).
  2. UMGCC basic researchers:
    • Dr. H. Ghandehari
      • Polymers for Targeted Delivery of Cancer Therapies (Support with animal experiments as Co-PI on R01 and DOD grants).
    • Dr. R.S. Hosmane (UMBC)
      • As part of a Cancer Center P30 Pilot Project FY06/07: Novel nucleoside analogues as potential cancer chemotherapeutics (drug screening in tumor cell lines and molecular pharmacology).
    • Dr. A. Hamburger/Dr. Zhang
      • Establishment of prostate cancer xenografts for studying the effect of Ebp1 on prostate tumor growth.
    • Dr. R. Gartenhaus
      • Role of MCT-1 in oncogenesis (In vitro and in vivo tumorigenicity assays, microscopy).
  3. Pharmaceutical industry users:
    • Komipharm, New York
      • Molecular Mechanism(s) of Action of KML001: Telomere Targeting and Effects on Telomerase Inhibition.

This page was last updated on: January 17, 2008.